Accelerate your Oncology Research
The aggressive pace of oncology research is characterized by large-scale, multidisciplinary efforts such as The Cancer Genome Atlas, The Human Protein Atlas, and Precision Medicine Initiative. With a broader and deeper understanding of the biology and signaling pathways that lead to cancer, scientists are better equipped to identify, characterize, and target biomarkers that can be translated into clinical applications. However, with these recent advancements comes a desperate need to understand the influence of the tumor microenvironment on cancer progression, evolution, and the resulting immune response. To make this next leap forward, scientists need tools that enable them to take an integrated, multi-omic, and 360° view of the tumor, immune response and microenvironment.
Novel single-cell cancer genomics studies and spatial biology have led to new insights on tumor heterogeneity. NanoString’s GeoMx Digital Spatial Profiling (DSP) technology allows for a thorough exploration of the complex interactions with the tumor microenvironment through visualization and quantification of transcripts and proteins on individual tissue sections
Coupled with nCounter expression panels focused on clinical research, immuno-oncology, cancer metabolism, and CAR-T cell therapy, NanoString provides solutions for every step of the way in cancer research, from bulk gene expression analysis to spatial profiling.
NanoString offers solutions that overcome the biggest challenges in cancer research:
- The complex interactions between the tumor and microenvironment
- A highly heterogeneous disease that leads to variable therapeutic response
- An ever-increasing number of possible therapeutic targets and combination trials
NanoString’s nCounter oncology gene expression panel portfolio has driven innovation since its inception, starting with the initial Hallmarks of Cancer Panel Collection and the best-selling PanCancer Immune Profiling Panel and PanCancer Pathways Panel. Expanding on this, the 360 Series Panel Collection and Data Analysis Service allow researchers to better understand therapeutic response/mechanism of action, immune evasion, and the interplay between the tumor and microenvironment.
Choose from curated, multiplexed nCounter Gene Expression Panels, GeoMx DSP RNA Assays, and/or GeoMx Protein Assays to build your next experiment and discover answers to your oncology research questions. Take advantage of the immune cell type signatures in nCounter expression panels to quantify the relative abundance of 14 different immune cell types as well as embedded signatures such as the 18-gene Tumor Inflammation Signature (TIS) in the 360 series panels.
Get a 360 view of cancer biology with 770 genes focused on the tumor, immune response, and the microenvironment. Pair the panel with the Data Analysis Service to receive 48 signature scores including TIS.
Study the interaction between the tumor, immune infiltrate, and the microenvironment in the context of breast cancer. Pair the panel with the Data Analysis Service to receive 48 signature scores including TIS, PAM50, and more.
Profile 780 genes across 40+ annotated pathways to study dysfunctional signaling pathways in cancer within the context of the interaction between the tumor, immune infiltrate, and the microenvironment. Includes genes for the TIS.
Characterize CAR-T cells and the T cell response to cancer with 780 genes focused on T cell activation, metabolism, fitness, phenotype, and exhaustion.
Profile Protein targets from a single FFPE tissue section or fresh frozen tissue slice and customize your assay with spike-in probes.
Profile 10’s-1000’s of RNA targets or >1,800 RNA targets with nCounter or NGS readout from a single FFPE or fresh frozen slide with Digital Spatial Profiling.
To help you in your quest to understand the oncology landscape, we’ve developed trusted solutions for every step of your research.
Preclinical and Clinical Research
Precise and flexible research solutions for preclinical research, drug development and assessment of therapeutic response. Focus areas include cell therapy, combination therapies, immunotherapy, comparative oncology, characterization of signaling pathways in response to targeted therapies, and mechanism of action (MoA) studies to assess the impact of a drug on its intended target.
Expression panels focused on altered metabolism of cancer cells, CAR-T cells, and other immune cell types.
Biomarker Discovery and Validation
Optimized products & protocols for identifying Coding RNA, Non-coding RNA, and protein biomakers. Tools to expedite signature development, including focused 360 Panels, Data Analysis Reports, and the Cancer Transcriptome Atals.
Tools for studying the impact of changes in the cancer genome. Predict MSI status, detect RNA fusions and quantify copy number variation (CNV).
Tailored solutions for visualizing cancer heterogeneity and metastatic tumors that focus on specific tumor types including hormone-driven tumors (e.g. breast, myeloma, leukemia/lymphoma and solid tumors).
A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer.
Cancer immunotherapies have generated remarkable clinical responses for some patients with advanced/metastatic disease, prompting exploration of rational combination therapies to bolster anti-tumor immunity in patients with limited response or those who experience tumor progression following an initial response to immunotherapy. In contrast to other tumor indications, objective response rates to single-agent PD-1/PD-L1 blockade in ovarian cancer are limited, suggesting a need to identify combinatorial approaches that lead to tumor regression in a setting where checkpoint blockade alone is ineffective.
Human breast microbiome correlates with prognostic features and immunological signatures in breast cancer.
BACKGROUND: Currently, over half of breast cancer cases are unrelated to known risk factors, highlighting the importance of discovering other cancer-promoting factors. Since crosstalk between gut microbes and host immunity contributes to many diseases, we hypothesized that similar interactions could occur between the recently described breast microbiome and local immune responses to influence breast cancer pathogenesis.
A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial.
Background: high recurrence rates of up to 75% within 2 years in pancreatic ductal adenocarcinoma (PDAC) patients resected for cure indicate a high medical need for clinical prediction tools and patient specific treatment approaches. Addition of the EGFR inhibitor erlotinib to adjuvant chemotherapy failed to improve outcome but its efficacy in some patients warrants predictors of responsiveness.